Satoeya N, Zack SR, Zoubi OA, Umar S, Burgos A, Abdulrab S, et al. Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF reprogrammed RA macrophages. Cell Mol Immunol. 2026;23:417–31.

Casey AM, Ryan DG, Prag HA, Chowdhury SR, Marques E, Turner K, et al. Pro-inflammatory macrophages produce mitochondria-derived superoxide by reverse electron transport at complex I that regulates IL-1β release during NLRP3 inflammasome activation. Nature Metabolism. 2025;7:493–507.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep. 2019;28:2455–70.e5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicenter, open-label, phase 4 randomized controlled trial. Lancet. 2021;397:305–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hogan AE, Davis C, Jenkins BJ, Jones N, O’Shea D. Repurposing metabolic drugs as anti-inflammatory agents. Trends Endocrinol Metab. 2025. https://doi.org/10.1016/j.tem.2025.07.003.

Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15:557–67.

Article  PubMed  CAS  Google Scholar 

Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, et al. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomized trials (contRAst 1 and contRAst 2). Ann Rheum Dis. 2023;82:1516–26.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nijjar JS, Abbott-Banner K, Alvarez Y, Aston N, Bass D, Bentley JH, et al. Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomized, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study. Ann Rheum Dis. 2025;84:856–65.

Article  PubMed  CAS  Google Scholar 

Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K. Predictors, demographics and frequency of sustained remission and low disease activity in antitumor necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2019;58:2162–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Keystone EC, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, et al. Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries. J Rheumatol. 2020;47:510–7.

Article  PubMed  CAS  Google Scholar